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Identiﬁcation of risk factors for chronic renal
failure is essential in order to prevent reduction
of life quality and life expectancy and to mini-
mize the high costs of treatment. Cadmium is
a widespread environmental pollutant known
to cause renal damage (Järup et al. 1998).
Apart from smoking, the major sources of cad-
mium exposure in the general population are
cereals, vegetables, and shellfish. There is
increasing evidence that toxic effects may occur
at much lower exposure levels (Alfven et al.
2000; Buchet et al. 1990; Järup et al. 2000;
Noonan et al. 2002) than those observed in
occupational settings or in severely polluted
environments. Still, the attempts to estimate
the level of critical exposure for kidney effects
have so far displayed large variations.
Furthermore, possible effects in populations
residing in areas with no particular industrial
cadmium emission are undetermined.
Cadmium accumulates in the renal cortex
and induces tubular toxicity (Barbier et al.
2005), which is ﬁrst detected as increased uri-
nary excretion of low-molecular-weight pro-
teins and tubular enzymes. Glomerular
dysfunction may also emerge, as demonstrated
in heavily exposed subjects (Järup et al. 1995;
Kido et al. 1990; Roels et al. 1989). It is not
known, however, whether the glomerulus is
affected by long-term low-level environmental
exposure. Diabetes, an increasing health
problem in many areas (King et al. 1998) and
one of the leading causes of incident end-stage
renal disease (Hostetter 2001), has been sug-
gested to augment the risk of cadmium-
induced kidney damage (Buchet et al. 1990).
Also, hypertension and intake of nephrotoxic
nonsteroid anti-inﬂammatory drugs (NSAIDs)
(Fored et al. 2001) might interact with cad-
mium. However, these possible interactions
need to be conﬁrmed.
The aim of the present investigation was to
assess the association between cadmium con-
centrations in blood and urine and a series of
markers of tubular and glomerular function.
To minimize dilution of the effects, we focused
on women at the age when the accumulation of
cadmium in the kidney is at its maximum.
Women have increased cadmium accumulation
compared with men (Järup et al. 1998; Nishijo
et al. 2004b), due to a higher dietary cadmium
absorption at low body iron stores (Åkesson
et al. 2002; Berglund et al. 1994). In addition,
we assessed whether diabetes, hypertension, and
the use of NSAIDs increased the risk. The
study was conducted in an area without partic-
ular industrial cadmium emission.
Materials and Methods
Study population. The Women’s Health in
the Lund Area (WHILA) study, a population-
based study of all women 50–59 years of age
in the community of Lund, southern Sweden
(n = 10,766), started in December 1995
(Lidfeldt et al. 2001) and was extended in
June 1999 to include health aspects of cad-
mium. This cohort was considered optimal
for elucidation of remaining questions about
dose–response relationships at low-dose cad-
mium exposure. The participation rate was
71% (n = 820). The exclusion criteria were
renal cancer (n = 1) and lithium treatment (n
= 3). Data were collected on various comor-
bidities, including diabetes and hypertension.
Women were classed as having diabetes if they
had a positive history, or if they had a non-
fasting glucose > 8 mmol/L followed by a pos-
itive result in the oral glucose-tolerance test.
Women were classed as hypertensive if they
had received antihypertensive treatment or
had a measured systolic and/or diastolic blood
pressure ≥ 160 and ≥ 95, respectively (mean
of two measurements after 15 min rest in
seated position). Lists of medications and data
on smoking were obtained, and weight and
height were measured. Participants were asked
to submit morning first-voided urine and
blood samples. We obtained morning spot
urine from 813 women and blood samples
from 742. All samples were collected during
8 months from June 1999 through January
2000. The ethics committee at Lund
University approved the WHILA study, and
oral informed consent was obtained.
Environmental Health Perspectives • VOLUME 113 | NUMBER 11 | November 2005 1627
Address correspondence to A. Åkesson, Institute of
Environmental Medicine, Division of Metals and
Health, Karolinska Institutet, Box 210, 171 77
Stockholm, Sweden. Telephone: 46-8-524-875-42.
Fax: 46-8-33-70-39. E-mail: Agneta.Akesson@
imm.ki.se
The late A. Schütz made invaluable contributions to
the study. We thank H. Ottosson, A. Akantis, A.-M.
Åberg, and B. Erdling for skillful technical assistance.
Funding was provided by the Swedish Research
Council/Medicine; Medical Faculty of Lund
University; Karolinska Institutet; the National
Swedish Environmental Protection Agency; the
Swedish Foundation for Strategic and Environmental
Research; the Swedish Society of Medicine, Primary
Care, R&D, County Council of Skåne; the Swedish
Research Council for Environment, Agricultural
Sciences, and Spatial Planning; and the Swedish
Council for Working Life and Social Research.
The authors declare they have no competing ﬁnancial
interests.
Received 21 February 2005; accepted 11 July 2005.
Tubular and Glomerular Kidney Effects in Swedish Women with
Low Environmental Cadmium Exposure
Agneta Åkesson,1 Thomas Lundh,2 Marie Vahter,1 Per Bjellerup,3 Jonas Lidfeldt,4 Christina Nerbrand,5
Göran Samsioe,6 Ulf Strömberg,2 and Staffan Skerfving2
1Institute of Environmental Medicine, Division of Metals and Health, Karolinska Institutet, Stockholm, Sweden; 2Department of
Occupational and Environmental Medicine, University Hospital, Lund, Sweden; 3Department of Clinical Chemistry, Karolinska University
Hospital, Huddinge, Sweden; 4Department of Community Health, Malmö University Hospital, Malmö, Sweden; 5Department of
Medicine, and 6Department of Gynecology and Obstetrics, University Hospital, Lund, Sweden
Cadmium is a well-known nephrotoxic agent in food and tobacco, but the exposure level that is criti-
cal for kidney effects in the general population is not deﬁned. Within a population-based women’s
health survey in southern Sweden (Women’s Health in the Lund Area, WHILA), we investigated
cadmium exposure in relation to tubular and glomerular function, from 1999 through early 2000 in
820 women (71% participation rate) 53–64 years of age. Multiple linear regression showed cad-
mium in blood (median, 0.38 µg/L) and urine (0.52 µg/L; density adjusted = 0.67 µg/g creatinine)
to be signiﬁcantly associated with effects on renal tubules (as indicated by increased levels of human
complex-forming protein and N-acetyl-β-D-glucosaminidase in urine), after adjusting for age, body
mass index, blood lead, diabetes, hypertension, and regular use of nephrotoxic drugs. The associa-
tions remained significant even at the low exposure in women who had never smoked. We also
found associations with markers of glomerular effects: glomerular ﬁltration rate and creatinine clear-
ance. Signiﬁcant effects were seen already at a mean urinary cadmium level of 0.6 µg/L (0.8 µg/g cre-
atinine). Cadmium potentiated diabetes-induced effects on kidney. In conclusion, tubular renal
effects occurred at lower cadmium levels than previously demonstrated, and more important,
glomerular effects were also observed. Although the effects were small, they may represent early
signs of adverse effects, affecting large segments of the population. Subjects with diabetes seem to
be at increased risk. Key words: cadmium, diabetes, environmental exposure, glomerular effects,
hypertension, kidney, lead, population-based, tubular effects, women. Environ Health Perspect
113:1627–1631 (2005). doi:10.1289/ehp.8033 available via http://dx.doi.org/ [Online 11 July 2005]
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Measurements included cadmium in blood as
a measure mainly of ongoing exposure
(expected to be fairly constant over time) and
urine as a measure of body burden (cadmium
in urine correlates well with cadmium in the
kidney cortex; Järup et al. 1998; Orlowski
et al. 1998). To control for possible confound-
ing/effect modification, we also determined
lead in blood (Lin et al. 2003). We used the
following effect markers: cystatin C in serum
(Dharnidharka et al. 2002) for calculation of
glomerular filtration rate (GFR), creatinine
clearance as markers of glomerular function,
and human complex-forming protein (protein
HC, α1-microglobulin), N-acetyl-β-D-
glucosaminidase (NAG), and calcium in urine
as markers of tubular damage. 
We measured cadmium, lead, and calcium
using inductively coupled plasma mass spec-
trometry (Barany et al. 1997). Cystatin C was
determined by immunonephelometry (Dade
Behring, Marburg, Germany). GFR = 77.24 ×
(cystatin C)–1.2623 (Larsson et al. 2004) and
creatinine clearance = [(140 – age) × body
weight (kg)]/[0.85 × serum creatinine (µM)]
(Harmoinen et al. 2003). Creatinine was
measured using a modified kinetic Jaffé
method (Roche Diagnostics, Mannheim,
Germany). We determined urinary protein
HC by Mancini technique and polyclonal
antibodies (DAKO A/S, Glostrup, Denmark)
(Järup et al. 2000), and urinary NAG with a
colorimetric method (Roche, Shionogi & Co.
Ltd., Osaka, Japan).
Urinary spot samples need to be adjusted
for dilution. Creatinine adjustment is most
common, but a comparison of density and
creatinine adjusted urinary cadmium indi-
cated that creatinine did not adjust for all
dilution-related variation of cadmium in
urine. Because creatinine excretion is depen-
dent upon meat intake and muscle mass
(Davies et al. 2002; Suwazono et al. 2005),
we chose to correct all urinary markers by the
mean urinary density (1.015 g/mL) according
to [urinary cadmium × (1.015 × 1,000) –
1,000]/[(urinary density × 1,000) – 1,000].
However, creatinine-adjusted values are given
for comparison.
Analytical performance. All the equipment
was tested, and possible contamination was
below the limit of detection. For cadmium and
lead in blood and cadmium and calcium in
urine, the limits of detection were 0.12 µg/L,
0.26 µg/L, 0.31 µg/L, and 1.6 mg/L, respec-
tively. For results below the limit of detection
(mainly urinary cadmium), the concentration
was set as the value factually obtained in the
analysis. The imprecision of the method, calcu-
lated as the coefﬁcient of variation for dupli-
cate measurements, was 7.4 and 3.1% for
cadmium and lead in blood and 8.5 and 6.4%
for cadmium and calcium in urine. The analyt-
ical accuracy for blood (Seronorm, batch
404107; Nycomed, Oslo, Norway) was as fol-
lows (mean ± SD): 0.67 ± 0.08 for cadmium
and 29 ± 1.1 for lead (n = 21; recommended,
0.67–0.70 and 31–39 µg/L, respectively). The
data for certiﬁed blood samples from the U.K.
National External Quality Assessment Service
(n = 11) deviated on average by ± 7.9% for
target values of 1.8–8.9 µg cadmium/L and
± 6.1% for 52–352 µg lead/L. The results
for urine (Seronorm, batch 102021) were
140 ± 8.1 mg/L (n = 20; recommended
130 mg/L) for calcium and 0.45 ± 0.07 µg/L
(n = 20; recommended, 0.35 µg/L) for cad-
mium. The result for the certiﬁed urine sam-
ples from Centre de Toxicologie du Quebec
Interlaboratory Comparison Program for cad-
mium was 0.76 ± 0.09 and 3.6 ± 0.22 µg/L (n
= 11; certiﬁed 0.79 and 3.6 µg/L), respectively.
The imprecision was 2.7% for cystatin C
(n = 6), 16% for protein HC (n = 10; limit of
detection = 0.7 mg/L), and < 10% for urinary
NAG (n = 68).
Statistical analyses. We used Spearman’s
rank correlation analysis to assess univariate
associations. The cadmium-associated kidney
effect markers were further evaluated in multi-
ple linear regression models, where each kid-
ney effect marker was evaluated in relation to
cadmium and confounders/covariates. The
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Table 1. Participant characteristics and data on exposure and kidney effect markers in a population-based
study from 1999 through early 2000 on 816 women in southern Sweden.
Variable (unit) Median (5–95% percentiles) No. of samples
Population characteristic
Age (years) 58 (54–63) 816
BMI (kg/m2) 26.2 (20.3–33.9)
Smokers: never/former/current (%) 54/25/21a
Diabetes: all/insulin dependent (%) 10/1.7a
Hypertension: all/drug treated (%) 31/18a
Regular use of NSAIDs (%) 6a
Exposure variables 
Blood cadmium (µg/L) 0.38 (0.16–1.8) 725
Urinary cadmium (µg/L)b 0.52 (0.24–1.3) 807
Urinary cadmium (µg/g creatinine) 0.67 (0.31–1.6)
Blood lead (µg/L) 22 (11–46) 726
Kidney effect markers
Serum cystatin C (mg/L) 0.81 (0.65–1.0) 721
GFR (mL/min)c 101 (74–133)
Serum creatinine (µmol/L) 92 (73–116) 713
Creatinine clearance (mL/min)d 72 (51–105)
Urinary protein HC (µg/L)b 2.4 (0.98–7.9) 806
Urinary protein HC (mg/g creatinine) 3.1 (0.13–1.2)
Urinary NAG (U/L)b 1.2 (0.22–3.6) 806
Urinary NAG (U/g creatinine) 1.4 (1.1–11)
Urinary calcium (mg/L)b 135 (56–267) 809
Urinary calcium (mg/g creatinine) 170 (62–366)
BMI, body mass index. 
aData are presented as percent. bAdjusted to mean density 1.015 g/mL. cCalculated: 77.24 × (serum cystatin C)–1.2623.
dCalculated: [(140 – age) × body weight (kg)]/[0.85 × serum creatinine (µM)]. Mean urinary creatinine = 0.85 g/L; conver-
sion factors: cadmium: 1 µg = 8.89 nmol; 1.0 µg/g creatinine ≈ 1.0 nmol/mmol creatinine; lead: 1 µg = 4.83 nmol. 
Table 2. Associations between exposure and effect markers (Spearman’s rank correlation coefﬁcients). 
Blood Urinary Serum Creatinine Urinary
Age BMI Pack-years cadmium cadmium Blood lead GFR creatinine clearance protein HC
Blood cadmium –0.01 –0.14# 0.56#
Urinary cadmium –0.02 –0.15# 0.42# 0.57#
Blood lead –0.03 –0.08* 0.18# 0.20# 0.15#
GFR –0.28# –0.27# –0.05 –0.13# –0.12# –0.11*
Serum creatinine 0.12* –0.08* 0.00 0.02 0.05 0.13# –0.38#
Creatinine clearance NR NR –0.02 –0.08* –0.13# –0.13# 0.11# –0.62#
Urinary protein HC 0.05 –0.18# 0.08* 0.15# 0.18# –0.01 –0.05 –0.02 –0.11*
Urinary NAG 0.06 –0.03 0.12# 0.13# 0.23# 0.02 –0.13# 0.09* –0.09* 0.21#
Urinary calcium –0.03 –0.04 –0.03 0.01 –0.02 0.12# 0.16# –0.15# 0.06 –0.04
Abbreviations: BMI, body mass index; NR, not relevant, as included in the calculation of creatinine clearance.
*p ≤ 0.05. #p ≤ 0.001. dependent effect markers (continuous) were
not dichotomized (Ragland 1992). No log-
transformation was needed as indicated by
residual and goodness-of-ﬁt analyses. We evalu-
ated possible effect modiﬁcation (interactions)
for cadmium and lead. Lowest observed effect
levels were assessed for each effect marker for
categorized urinary cadmium using Dunnett’s
post hoc test, including signiﬁcant confounders
and covariates in the models. All tests were two
sided, and statistics were performed using SPSS
(version 12.01; SPSS Inc., Chicago, IL, USA).
Results
The study population characteristics, expo-
sure variables, and kidney effect markers are
presented in Table 1. The proportion of sub-
jects with diabetes was slightly higher in the
present study compared with those participat-
ing in the whole WHILA cohort (6.4%)
(Lidfeldt 2003). The proportion of hyper-
tensive subjects was, however, similar
(Lidfeldt 2003). Those who had ever smoked
had 90% higher cadmium concentrations in
blood and 40% higher in urine compared
with never-smokers, who had 0.30 µg/L and
0.45 µg/L cadmium in blood and urine,
respectively.
The univariate associations between cad-
mium and kidney effect markers as well as
those with possible confounders and effect
modiﬁers are shown in Table 2. Cadmium in
both blood and urine was associated with all
kidney effect markers except serum creatinine
and urinary calcium, which were not included
in further analysis. Using cystatin C instead of
estimated GFR, and creatinine-adjusted
markers in urine instead of density adjusted
ones had no major impact on the results.
Multivariate analyses. In the multiple lin-
ear regression analysis, each of the cadmium-
associated kidney effect markers was tested
separately, as were cadmium levels in urine and
blood (Table 3). We included in the models
the covariates age, body mass index (BMI), and
blood lead, as well as the possible kidney-effect
modifiers diabetes, hypertension, and use of
NSAIDs. Never-smokers were analyzed sepa-
rately. Cadmium in urine was significantly
associated with GFR, creatinine clearance, pro-
tein HC, and NAG, after controlling for con-
founders and adjusting for other covariables
(Table 3). Similar results were obtained for
blood cadmium. In never-smokers, cadmium
remained associated with protein HC and
NAG and became signiﬁcantly associated with
creatinine clearance (blood cadmium). Lead
was signiﬁcantly associated with GFR and cre-
atinine clearance.
Because there were no associations between
cadmium and GFR or creatinine clearance (for
urinary cadmium) in never-smokers, we tested
whether there was confounding through a
non-cadmium-dependent effect of smoking
by including pack-years in the multiple
regression models. Smoking (pack-years) was
not signiﬁcantly associated with GFR or crea-
tinine clearance (p ≥ 0.1).
We assessed possible interactions between
cadmium and blood lead, diabetes (insulin-
treated vs. the rest), hypertension, or use of
NSAIDs, and between blood lead and dia-
betes, hypertension, or use of NSAIDs. For
NAG, there was an interaction between uri-
nary cadmium and diabetes (insulin-treated
vs. other diabetics and nondiabetics; regression
coefﬁcients (β): diabetics = 2.3, nondiabetics =
0.8; R2 = 0.10; p = 0.042) (Table 3). For pro-
tein HC, there was a close to signiﬁcant inter-
action between urinary cadmium and diabetes
(β: diabetics = 4.0, nondiabetics = 1.3; R2 =
0.09; p = 0.07), which became signiﬁcant in
never-smokers (β: diabetics = 27, nondiabetics
= 1.9; R2 = 0.18; p < 0.001). Similar interac-
tions were observed between blood cadmium
and diabetes. Hypertension, NSAID use, and
Cadmium-induced effects on kidney
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Table 3. Associations between markers of cadmium exposure and effects in a population-based study on 816
Swedish women, allowing for other risk factors, performed in all subjects and never-smokers separately. 
Dependent Independent All Never-smokers
variable variable β 95% CI R2 β 95% CI R2
GFR Urinary cadmium (µg/L) –7.9 –11 to –4.3 0.15 –5.0 –11 to 0.9 0.16
(mL/min) Age (year) –1.5 –1.9 to –1.0 –1.3 –1.9 to –0.7
BMI (kg/m2) –1.0 –1.3 to –0.7 –1.1 –1.5 to –0.7
Blood lead (µg/L) –0.20 –0.32 to –0.09 –0.26 –0.43 to –0.09
Diabetesa NS –25 –46 to –5.0
Hypertensionb NS NS 
NSAIDsc –6.8 –12 to –1.2 NS 
Blood cadmium –4.2 –6.6 to –1.9 0.15 –6.0 –15 to 3.0 0.16
Age (year) –1.5 –1.9 to –1.0 –1.2 –1.8 to –0.7
BMI (kg/m2) –1.0 –1.3 to –0.7 –1.1 –1.6 to –0.7
Blood lead (µg/L) –0.2 –0.3 to –0.07 –0.2* –0.4 to –0.07
Diabetes NS  –25 –45 to –4.8
Hypertension NS NS 
NSAIDs –6.1 –12 to –0.5 NS 
Creatinine Urinary cadmium (µg/L) –4.3 –8.0 to –0.7 0.03 –3.5 –9.9 to 2.8 0.05
clearance Blood lead (µg/L) –0.18 –0.30 to –0.06 –0.3 –0.5 to –0.1
(mL/min) Diabetes NS –29 –51 to –8.0
Hypertension NS NS
NSAIDs NS NS
Blood cadmium –1.6 –4.0 to 0.7 0.03 –9.8 –19 to –0.5 0.06
Blood lead (µg/L) –0.18 –0.30 to –0.07 –0.3 –0.5 to –0.1
Diabetes NS –29 –50 to –8.0
Hypertension 3.0 0.3 to 5.9 NS
NSAIDs NS NS
Urinary Urinary cadmium (µg/L) 1.4 0.9 to 1.8 0.09 2.1* 1.3 to 2.8 0.13
protein Age (year) NS NS
HC (µg/L) BMI (kg/m2) –0.06 –0.10 to –0.02 –0.08 –0.13 to –0.02
Blood lead (µg/L) NS NS
Diabetes 3.5 2.2 to 4.9 5.1 3.1 to 7.1
Hypertension NS 0.57 0.05 to 1.1
NSAIDs NS NS
Blood cadmium 0.5 0.2 to 0.8 0.06 1.7* 0.5 to 3.0 0.09
Age (year) NS NS
BMI (kg/m2) –0.07 –0.11 to –0.02 –0.08 –0.14 to –0.02
Blood lead (µg/L) NS NS
Diabetes 3.5 2.2 to 4.8 5.8 3.4 to 8.1
Hypertension NS NS
NSAIDs NS NS
Urinary Urinary cadmium (µg/L) 0.9* 0.6 to 1.1 0.09 0.8 0.4 to 1.2 0.10
NAG (U/L) Age (year) NS NS
BMI (kg/m2)N S N S
Blood lead (µg/L) NS NS
Diabetes 1.5 0.9 to 2.2 3.0 1.9 to 4.1
Hypertension NS NS
NSAIDs NS NS
Blood cadmium 0.4 0.2 to 0.5 0.05 0.5 –0.05 to 1.1 0.06
Age (year) NS NS
BMI (kg/m2)N S N S
Blood lead (µg/L) NS NS
Diabetes 1.5 0.8 to 2.1 2.9 1.7 to 4.0
Hypertension NS NS
NSAIDs NS NS
Abbreviations: β, regression coefﬁcient; 95% CI, 95% conﬁdence interval; adjusted R2, explained variance; NS, not signiﬁcant.
aInsulin treated vs. all others, yes = 1. bHypertension, yes = 1. cNSAIDs, yes = 1. *Significant interaction with diabetes
(described in text).blood lead showed no signiﬁcant interactions
with cadmium exposure. However, there was
an interaction between blood lead and dia-
betes for GFR in never-smokers (p = 0.005).
Lowest observed effect level. Protein HC,
NAG (diabetics excluded) (Figure 1A), and cre-
atinine clearance (Figure 1B), after adjustment
for blood lead, differed signiﬁcantly between
the group with lowest exposure level (urinary
cadmium < 0.5 µg/L; mean, 0.36 µg cad-
mium/L = 0.48 µg cadmium/g creatinine) and
that with the next lowest exposure level
(0.50–0.75 µg/L; mean, 0.61 µg cadmium/L =
0.79 µg cadmium/g creatinine). For GFR, the
group with the next highest exposure level [uri-
nary cadmium, 0.75–1 µg cadmium/L; mean,
0.86 µg cadmium/L = 1.0 µg cadmium/g crea-
tinine; adjusted for age, BMI, and blood lead
(each categorized into four groups) and for
NSAID use (into 0 or 1); Figure 1C] differed
from the lowest level. For blood cadmium,
associations were present in the exposure cate-
gory 0.5–1 µg/L (mean, 0.69 µg/L) for protein
HC (p = 0.036) and NAG (p = 0.024). For
GFR, an association was seen only at blood
cadmium > 1 µg/L (mean, 1.8 µg/L; p < 0.001)
after adjustment for signiﬁcant covariates.
Discussion
This population-based study of upper-middle-
age women, representative of the general popu-
lation of southern Sweden, showed clear
associations between cadmium and the renal
tubular-effect markers protein HC and NAG,
even at the low levels of cadmium found in
never-smokers. Cadmium potentiated the dia-
betes-induced effects on the kidney. There was
also a clear association between cadmium and
GFR or creatinine clearance.
This study has several methodologic
advantages, including the large sample size and
high participation rate, individual exposure
assessment with high analytical accuracy, and
inclusion of several different outcomes of renal
effects. Despite the low cadmium concentra-
tions, we had a high analytical accuracy. Any
imprecision would have caused a bias toward
the null.
The study population differed somewhat
from the total WHILA population and Sweden
(4–7%) (Lidfeldt 2003). Hence, there was a
slight overrepresentation of diabetics, which
may cause an overestimate of cadmium effects.
However, because we controlled for diabetes in
the statistical models, this is not a problem.
Overcontrol and collinearity may occur in a sta-
tistical analysis such as that performed in this
study. Smoking is then an obvious problem,
which we handled by separate analysis in never-
smokers. Lead and BMI were included, which
means a risk of some overcontrol.
Another problem, common in the inter-
pretation of data from cross-sectional studies, is
that the exposure is measured at the same time
as the effects, which may not be the etiologi-
cally relevant period. This may be problematic
for blood cadmium, because it largely reﬂects
recent exposure, but not for urinary cadmium,
which is a good estimate of the integrated low-
level exposure over decades (Järup et al. 1998).
It is known that kidney deterioration, due to
both aging and high cadmium exposure,
increases the excretion of cadmium in urine,
resulting in lower kidney cadmium and even-
tually lower urinary cadmium. However, the
present participants were below the age when
the kidney cadmium starts to decrease, and the
exposure was relatively low.
The present cadmium concentrations are
comparable with, or slightly higher than, those
in other recent studies from Sweden (Åkesson
et al. 2002; Järup et al. 2000; Olsson et al.
2002) and the United States [Centers for
Disease Control and Prevention (CDC) 2003;
Noonan et al. 2002; Paschal et al. 2000] but
lower than those in more contaminated areas
of Europe (Buchet et al. 1990; Hotz et al.
1999) and much lower than in certain areas in
Japan (Suwazono et al. 2000; Yamanaka et al.
1998). Despite the present low cadmium lev-
els, there were clear effects on the kidney. The
associations between cadmium and biomarkers
of several different renal effects support causal-
ity. It is unlikely that they are merely a result of
parallel phenomena, impaired tubular reab-
sorption (protein HC), or increased general
turnover of tubular cells (NAG). The associa-
tions with blood cadmium also preclude such
an interpretation. Because smoking is a major
source of cadmium exposure (Järup et al.
1998), the possibility of confounding through
a non-cadmium-dependent effect of smoking
must be considered. However, because we
found cadmium-associated effects on NAG
and protein HC even in never-smokers, and
there was no effect of smoking on creatinine
clearance or GFR, this is unlikely.
The lead levels were low. The association
between blood lead and GFR and creatinine
clearance may indicate either an effect on
GFR at low lead exposure (Lin et al. 2003) or
reverse causality. In the case of cadmium,
reverse causality seems highly unlikely. Even
though data may imply that a decrease in
GFR causes increased blood cadmium concen-
trations, the inverse associations between the
glomerular effect markers and cadmium in
urine rather indicate that reduced GFR does
not reduce the clearance of cadmium. In addi-
tion, lead is bound to high-molecular-weight
plasma albumin, and cadmium to metallo-
thionein, a small polypeptide that is easily
ﬁltered through the glomerulus.
The lowest observed effect level, deﬁned as
the mean urinary cadmium in the exposure
category that displayed signiﬁcantly different
Åkesson et al.
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Figure 1. Associations (crude) between urinary NAG (A), creatinine clearance (B), and GFR (C) and urinary cadmium (categorized) in a population-based study
from 1999 through early 2000 on 816 women in southern Sweden. Boxes indicate 25th, 50th (solid line), and 75th percentiles, and whiskers indicate minimum and
maximum, excluding outliers (circles; a few, not shown in the ﬁgure but included in all the calculations). Numbers inside boxes indicate the number of samples.
The dashed line indicates the median in the lowest urinary cadmium exposure category. p-Values for differences between the lowest exposure group and the fol-
lowing groups are indicated (Dunnett’s test including the signiﬁcant confounders and covariates according to Table 3). 
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levels of effect markers compared with the
lowest urinary cadmium category, was 0.6 µg
cadmium/L (0.8 µg/g creatinine), correspond-
ing to approximately 20 µg cadmium/g kidney
cortex. The lowest observed effect level is
lower than in previous studies that observed
effects at low-level cadmium exposure (Buchet
et al. 1990; Järup et al. 2000; Noonan et al.
2002). This is probably due to homogeneity
of the population, absence of healthy worker
effects (Järup et al. 2000), and good precision
in analyses of the exposure and effect markers.
More important, we found a similar lowest
observed effect level for creatinine clearance as
for the tubular markers. Although usually con-
sidered an index of glomerular function, the
creatinine clearance may partly reﬂect a proxi-
mal tubular dysfunction, because creatinine is
not only ﬁltrated but also secreted in the tubuli
(Wuyts et al. 2003). On the other hand, the
cadmium-associated increase in GFR, occur-
ring in the next highest cadmium stratum
(0.86 µg/L urine = 1.0 µg/g creatinine), clearly
indicates an effect on the glomerular function.
An observation in this contex that supports an
effect of cadmium on GFR is the reported eco-
logic association between end-stage renal dis-
ease and distance to cadmium-emitting
industrial plants (Hellström et al. 2001). 
Cadmium has been suggested to cause
hypertension, but no such effect was seen here,
in agreement with other studies (Staessen et al.
2000). Also, we did not observe any synergism
between cadmium and hypertension on the
kidney effects. However, there might be a dilu-
tion of the group by cases with mild hyperten-
sion. Further, it has been reported, both from
experimental and epidemiologic studies, that
cadmium increases the risk of type II diabetes
(Han et al. 2003; Schwartz et al. 2003), which
was not supported by the present study. As
expected, diabetes affected the kidney function,
although only in insulin-dependent women, of
whom about half had type II diabetes. More
important, we found an interaction between
cadmium and diabetes, as suggested in previ-
ous studies (Buchet et al. 1990). Hence, the
lowest observed effect level is expected to be
lower in diabetics but could not be evaluated
because of too few cases. The incidence of dia-
betes is increasing (King et al. 1998), and
because diabetes is the leading cause of end-
stage renal disease (Hostetter 2001), this has
important public health implications. The inci-
dence of renal replacement therapy in Sweden
is 125 per million, with an estimated increased
prevalence of 5% per year (Swedish National
Board of Health and Welfare 2003). 
The nephrotoxic effects in the present study
appear small in a clinical context, and only a
few percent of the variances were explained by
cadmium. However, the increase in the effect
markers indicates renal toxicity, which should
be considered an early sign of severe health
effects (Nishijo et al. 2004a). Because it
concerns a large segment of the population
worldwide, the results are of public health con-
cern. Although the cadmium-induced kidney
effects in several studies have been associated
with decreasing GFR (Järup et al. 1995; Kido
et al. 1990; Roels et al. 1989), a positive aspect
is that progression of the very early effect may
not always occur when the exposure is substan-
tially decreased (Hotz et al. 1999). It should,
however, be emphasized that in areas with
exposure to cadmium mainly through diet, the
long half-time of cadmium in the soil will
hamper a decrease of the exposure. Thus, far-
reaching mitigation will be needed in addition
to actions against smoking.
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